Relaxin gene therapy: A promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis

JinWoo Hong; Chae-Ok Yun

doi:10.1016/j.mce.2019.01.009

Relaxin gene therapy: A promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis

Mol Cell Endocrinol. 2019 May 1:487:80-84. doi: 10.1016/j.mce.2019.01.009. Epub 2019 Jan 11.

Authors

JinWoo Hong¹, Chae-Ok Yun²

Affiliations

¹ Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, 133-791, Seoul, Republic of Korea.
² Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, 133-791, Seoul, Republic of Korea; Institute of Nano Science and Technology (INST), Hanyang University, Republic of Korea. Electronic address: chaeok@hanyang.ac.kr.

PMID: 30641100
DOI: 10.1016/j.mce.2019.01.009

Abstract

Relaxin (RLX) is an insulin-like polypeptide hormone that was initially introduced for its pregnancy-related function. Subsequent studies revealed that RLX possesses anti-fibrotic functions in tumors and nonreproductive tissues, such as skin, lungs, and others. This aspect of the RLX has been explored for the treatment of various illnesses, such as cardiac fibrosis, liver fibrosis, and solid tumors. With gene therapy coming into age with increasing number of products being approved by regulatory bodies in Europe and United States, we aim to discuss how RLX have been utilized in scope of gene therapy for treatment of various illnesses.

Keywords: Cancer; Cardiac dysfunction; Gene therapy; Liver cirrhosis; Relaxin.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Disease*
Fibrosis
Humans
Neovascularization, Pathologic / therapy*
Relaxin / genetics*
Relaxin / therapeutic use*
Wound Healing

Substances

Relaxin